Polymorphisms in SLCO1B1 and UGT1A1 are Associated with Sorafenib-Induced Toxicity

References

• Llovet JM , RicciS , MazzaferroVet al. Sorafenib in advanced hepatocellular carcinoma . N. Engl. J. Med.359 ( 4 ), 378 – 390 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Cheng AL , KangYK , ChenZet al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial . Lancet Oncol.10 ( 1 ), 25 – 34 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Escudier B , EisenT , StadlerWMet al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial . J. Clin. Oncol.27 ( 20 ), 3312 – 3318 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Shimada M , OkawaH , KondoYet al. Monitoring serum levels of sorafenib and its N-oxide is essential for long-term sorafenib treatment of patients with hepatocellular carcinoma . Tohoku J. Exp. Med.237 ( 3 ), 173 – 182 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fukudo M , ItoT , MizunoTet al. Exposure–toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma . Clin. Pharmacokinet.53 ( 2 ), 185 – 196 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fucile C , MarencoS , BazzicaMet al. Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study . Med. Oncol.32 ( 1 ), 335 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Vasilyeva A , DurmusS , LiLet al. Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b . Cancer Res.75 ( 13 ), 2729 – 2736 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bins S , Van DoornL , GibsonAet al. 305 Influencing sorafenib disposition by blocking hepatocellular sorafenib-glucuronide uptake with rifampin in mice and humans . Eur. J. Cancer51 , S56 ( 2015 ).
   Web of Science ®Google Scholar
• Jain L , SissungTM , DanesiRet al. Hypertension and hand–foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib . J. Exp. Clin. Cancer Res.29 , 95 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Han JY , LimHS , ShinESet al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer . Lung Cancer59 ( 1 ), 69 – 75 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Teft WA , WelchS , LenehanJet al. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy . Br. J. Cancer112 ( 5 ), 857 – 865 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Picard N , YeeSW , WoillardJBet al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics . Clin. Pharmacol. Ther.87 ( 1 ), 100 – 108 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tsuchiya N , NaritaS , InoueTet al. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma . Anticancer Drugs24 ( 3 ), 310 – 314 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Han JY , LimHS , YooYKet al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer . Cancer110 ( 1 ), 138 – 147 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Eechoute K , SparreboomA , BurgerHet al. Drug transporters and imatinib treatment: implications for clinical practice . Clin. Cancer Res.17 ( 3 ), 406 – 415 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cusatis G , GregorcV , LiJet al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib . J. Natl Cancer Inst.98 ( 23 ), 1739 – 1742 ( 2006 ).
   PubMedGoogle Scholar
• Koo DH , RyuMH , RyooBYet al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor . Cancer Chemother. Pharmacol.75 ( 1 ), 173 – 182 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P , NarjozC , GolmardJLet al. Early sorafenib-induced toxicity is associated with drug exposure and UGT1A9 genetic polymorphism in patients with solid tumors: a preliminary study . PLoS ONE7 ( 8 ), e42875 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Peer CJ , SissungTM , KimAet al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia . Clin. Cancer Res.18 ( 7 ), 2099 – 2107 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Liu X , ChengD , KuangQ , LiuG , XuW . Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians . Pharmacogenomics J.14 ( 2 ), 120 – 129 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• de Jong FA , de JongeMJ , VerweijJ , MathijssenRH . Role of pharmacogenetics in irinotecan therapy . Cancer Lett.234 ( 1 ), 90 – 106 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Zimmerman EI , RobertsJL , LiLet al. Ontogeny and sorafenib metabolism . Clin. Cancer Res.18 ( 20 ), 5788 – 5795 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ghassabian S , RawlingT , ZhouFet al. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites . Biochem. Pharmacol.84 ( 2 ), 215 – 223 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Elens L , van GelderT , HesselinkDA , HaufroidV , van SchaikRH . CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy . Pharmacogenomics14 ( 1 ), 47 – 62 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lathia C , LettieriJ , CihonF , GallentineM , RadtkeM , SundaresanP . Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics . Cancer Chemother. Pharmacol.57 ( 5 ), 685 – 692 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Machiela MJ , ChanockSJ . LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants . Bioinformatics31 ( 21 ), 3555 – 3557 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lewis CM . Genetic association studies: design, analysis and interpretation . Brief. Bioinform.3 ( 2 ), 146 – 153 ( 2002 ).
   PubMedGoogle Scholar
• Lee JH , ChungYH , KimJAet al. Genetic predisposition of hand–foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma . Cancer119 ( 1 ), 136 – 142 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Qin C , CaoQ , LiPet al. The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma . Sci. Rep.6 , 20089 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Meza-Junco J , ChuQS , ChristensenOet al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib . Cancer Chemother. Pharmacol.65 ( 1 ), 1 – 4 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Culley CL , KiangTK , GilchristSE , EnsomMH . Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review . Ann. Pharmacother.47 ( 4 ), 561 – 572 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shibata T , MinamiY , MitsumaAet al. Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia . Int. J. Clin. Oncol.19 ( 2 ), 391 – 396 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ieiri I , HiguchiS , SugiyamaY . Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs . Expert Opin. Drug Metab. Toxicol.5 ( 7 ), 703 – 729 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Swift B , NebotN , LeeJKet al. Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites . Drug Metab. Dispos.41 ( 6 ), 1179 – 1186 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kivisto KT , NiemiM . Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans . Pharm. Res.24 ( 2 ), 239 – 247 ( 2007 ).
   PubMed Web of Science ®Google Scholar